Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Comprehensive Dosing Guide
Special Considerations
Kidney Problems:
- Usually no need to change the dose.
- Be careful if you have severe kidney issues.
Liver Problems:
- Use carefully if you have moderate or severe liver issues.
Older Adults:
- No dose changes needed, but watch for side effects.
Children:
- Not approved for use in kids as of October 2023. Check with your doctor for updates.
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.